Pharmaceutical industry – Page 2
-
FeaturePutting the F in pharma
Adding fluorine to drug molecules can be tricky, but is often worthwhile. Rachel Brazil talks to the chemists trying to tame the ninth element
-
ResearchFar more drugs could be taken orally by formulating them with silica nanoparticles
Many more medicines could be made water soluble making taking them easier for patients
-
BusinessNew Purdue bankruptcy deal cuts out Sacklers’ legal immunity
$7.4 billion proposal will fund support for victims of US opioid crisis
-
BusinessJ&J’s Intra-Cellular deal could signal more mega-mergers for 2025
£15 billion deal for neuroscience biotech aims to replace revenues from patent expiries
-
OpinionSharing the burden of contraception could also mean sharing the risk
What if risk assessments for contraception considered the sum of risk to both members of a couple?
-
FeatureOn the trail of the male contraceptive pill
As multiple novel male contraception compounds enter clinical trials, is family planning about to undergo a second revolution? James Mitchell Crow reports
-
OpinionRobots queuing up to fail
Claims of an AI revolution in drug discovery are missing the biggest problem
-
BusinessAthira pharma settles research misconduct charges for $4 million
Deal with US Department of Justice resolves allegations against former chief executive
-
FeatureThe promise of drugs that send proteins to the shredder
Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to strategic discovery
-
WebinarHarnessing hormones for health: Taking GLP-1 from research to reality
Learn about the groundbreaking science research behind the GLP-1 revolution
-
BusinessPharmaceuticals roundup 2024
Diabetes and weight loss drugs have surged in popularity, revealing supply frailties
-
-
-
BusinessEurope reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
-
BusinessUS government moves to block J&J talc bankruptcy resolution
Firm’s third attempt to shift claims to a subsidiary had gained significant support
-
BusinessSanofi spins out its consumer healthcare business
US-based investment firm takes controlling stake in Opella, while France’s government moves to ensure the company remains in the country
-
BusinessDrug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
-
BusinessUS approves schizophrenia drug with new mode of action
Cobenfy promises to better address negative symptoms than existing antipsychotics
-
WebinarThe science and promise of liquid biopsies: improving cancer treatment
Learn how liquid biopsies are being used to identify cancer and improve patient outcomes
-
OpinionA chemist in the flower garden
The beautifully complex molecules plants produce are as inspiring as the blooms themselves